IDNA Genomics Public Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-2.51	-2.52	-1.34
Depreciation & Amortization	0.21	0.29	0.24
Loss (Gain) From Sale of Assets	-	-	-0.09
Asset Writedown & Restructuring Costs	1.34	1.34	-
Other Operating Activities	-0.49	-0.3	0.14
Change in Accounts Receivable	-0.09	-0.12	-0.02
Change in Inventory	-0.03	-0.05	-0.05
Change in Accounts Payable	-1.26	-1.15	1.12
Operating Cash Flow	-2.76	-2.52	-0.01
Capital Expenditures	-0.01	-0.01	-0
Divestitures	2	2	-
Sale (Purchase) of Intangibles	-	-0.16	-0.7
Investment in Securities	-0.01	-0.01	-0.02
Investing Cash Flow	1.98	1.82	-0.72
Long-Term Debt Issued	-	-	1.56
Long-Term Debt Repaid	-	-0.12	-0.75
Net Debt Issued (Repaid)	-0.25	-0.12	0.81
Other Financing Activities	-0.19	-0.15	-0.13
Financing Cash Flow	-0.45	-0.26	0.68
Net Cash Flow	-1.22	-0.96	-0.05
Free Cash Flow	-2.77	-2.53	-0.01
Free Cash Flow Margin	-540.44%	-528.51%	-2.62%
Free Cash Flow Per Share	-1.00	-0.92	-0.01
Cash Interest Paid	0.19	0.15	0.13
Cash Income Tax Paid	0.01	0.01	-
Levered Free Cash Flow	-	-2.21	-
Unlevered Free Cash Flow	-	-2.12	-
Change in Working Capital	-1.38	-1.32	1.05

Source: S&P Global Market Intelligence. Standard template. Financial Sources.